The Impact of Velcade [bortezomib] on Antibody Secreting Cells in Sensitized Renal Allograft Candidates.

Trial Profile

The Impact of Velcade [bortezomib] on Antibody Secreting Cells in Sensitized Renal Allograft Candidates.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 01 Jul 2016 Results published in the Transplantation
    • 28 Apr 2016 Treatment arms changed from 1 to 3 with 4, 16 and 32 dose groups.
    • 28 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top